07 May 2021>: Clinical Research
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
Anthony Matta 123ABCDEF , Vanina Bongard 12ABCDEF , Frédéric Bouisset 12ABCDEF , Dorota Taraszkiewicz 12ABCDEF , Jean-Pierre Rabès 4BDEF , Jean Ferrières 12ABCDEFG*DOI: 10.12659/MSM.928784
Med Sci Monit 2021; 27:e928784
Table 2 Analysis of variance (ANOVA) comparing the reduction in mean low-density lipoprotein cholesterol between the 3 groups after adding PCSK9i.
Mean variation in LDL-c (mg/dl±SD) | Compared to | 95% CI | P value | |
---|---|---|---|---|
PCSK9i | 125±60 | PCSK9i+statin | (−0.85; −0.15) | 0.002 |
PCSK9i+ezetimibe | (−0.28; 0.72) | 0.86 | ||
PCSK9i+ezetimibe | 103±89 | PCSK9i | (−0.72; 0.28) | 0.86 |
PCSK9i+statin | (−1.28; −0.17) | 0.006 | ||
PCSK9i+statin and ezetimibe | 175±72 | PCSK9i | (0.15; 0.85) | 0.002 |
PCSK9i+ezetimibe | (0.17; 1.28) | 0.006 | ||
CI – confidence interval; HDL-c – high-density lipoprotein cholesterol; LDL-c – low-density lipoprotein cholesterol; PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitors. |